Jennison Associates’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,264,546
| Closed | -$176M | – | 587 |
|
|
2026
Q1 | $176M | Buy |
1,264,546
+375,359
| +42% | +$52.6M | 0.12% | 83 |
|
|
2025
Q4 | $109M | Buy |
889,187
+741,044
| +500% | +$90.1M | 0.07% | 125 |
|
|
2025
Q3 | $16.4M | Sell |
148,143
-499,194
| -77% | -$56.7M | 0.01% | 341 |
|
|
2025
Q2 | $71.8M | Buy |
+647,337
| New | +$68.9M | 0.04% | 167 |
|
|
2025
Q1 | – | Sell |
-943,628
| Closed | -$87.2M | – | 597 |
|
|
2024
Q4 | $87.2M | Buy |
+943,628
| New | +$85M | 0.05% | 154 |
|
|
2021
Q2 | – | Sell |
-540,103
| Closed | -$34.9M | – | 697 |
|
|
2021
Q1 | $34.9M | Buy |
+540,103
| New | +$34.8M | 0.03% | 272 |
|
|
2020
Q2 | – | Sell |
-21,587
| Closed | -$1.61M | – | 657 |
|
|
2020
Q1 | $1.61M | Buy |
+21,587
| New | +$1.49M | ﹤0.01% | 454 |
|
|
2018
Q2 | – | Sell |
-41,255
| Closed | -$3.11M | – | 674 |
|
|
2018
Q1 | $3.11M | Buy |
41,255
+33,219
| +413% | +$2.64M | ﹤0.01% | 500 |
|
|
2017
Q4 | $576K | Sell |
8,036
-15,969
| -67% | -$1.21M | ﹤0.01% | 621 |
|
|
2017
Q3 | $1.95M | Buy |
+24,005
| New | +$1.84M | ﹤0.01% | 546 |
|
|
2017
Q1 | – | Sell |
-21,348
| Closed | -$1.53M | – | 702 |
|
|
2016
Q4 | $1.53M | Buy |
+21,348
| New | +$1.59M | ﹤0.01% | 571 |
|
|
2016
Q2 | – | Sell |
-9,147
| Closed | -$840K | – | 640 |
|
|
2016
Q1 | $840K | Sell |
9,147
-210,534
| -96% | -$19M | ﹤0.01% | 566 |
|
|
2015
Q4 | $22.2M | Sell |
219,681
-2,561,694
| -92% | -$267M | 0.02% | 411 |
|
|
2015
Q3 | $273M | Sell |
2,781,375
-6,502,089
| -70% | -$722M | 0.28% | 73 |
|
|
2015
Q2 | $1.09B | Sell |
9,283,464
-394,099
| -4% | -$43.1M | 1% | 23 |
|
|
2015
Q1 | $950M | Sell |
9,677,563
-749,701
| -7% | -$76.1M | 0.87% | 31 |
|
|
2014
Q4 | $983M | Sell |
10,427,264
-3,029,805
| -23% | -$313M | 0.92% | 35 |
|
|
2014
Q3 | $1.43B | Sell |
13,457,069
-398,940
| -3% | -$39.1M | 1.33% | 10 |
|
|
2014
Q2 | $1.15B | Sell |
13,856,009
-2,059,749
| -13% | -$160M | 1.06% | 24 |
|
|
2014
Q1 | $1.13B | Sell |
15,915,758
-313,104
| -2% | -$24.6M | 1.08% | 22 |
|
|
2013
Q4 | $1.22B | Sell |
16,228,862
-7,985,052
| -33% | -$556M | 1.2% | 15 |
|
|
2013
Q3 | $1.52B | Sell |
24,213,914
-901,203
| -4% | -$53.9M | 1.6% | 7 |
|
|
2013
Q2 | $1.29B | Buy |
+25,115,117
| New | +$1.31B | 1.45% | 10 |
|
Other funds holding GILD
Jennison Associates's GILD Position: Q2 2026 in Review
Jennison Associates sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,264,546 shares — an estimated $176M sold.
Jennison Associates first reported a position in GILD in Q2 2013 and held it in 23 quarters. The position peaked at $1.52B in Q3 2013. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Jennison Associates reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
- Jennison Associates sold 1,264,546 Gilead Sciences shares in Q2 2026, an estimated $176M.
- Jennison Associates first reported a position in Gilead Sciences in Q2 2013 and held it in 23 quarters.
- Jennison Associates's Gilead Sciences position peaked at $1.52B in Q3 2013.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.